Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 22505121)

1.

Comparison of hepatitis C virus treatment between incarcerated and community patients.

Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, Sawyer J, Striker R, Lucey MR.

Hepatology. 2012 Oct;56(4):1252-60. doi: 10.1002/hep.25770.

PMID:
22505121
2.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

3.

Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.

Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P.

J Viral Hepat. 2011 Jul;18(7):513-7. doi: 10.1111/j.1365-2893.2010.01340.x. Epub 2010 Jun 21.

PMID:
20565572
4.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

5.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

6.
7.

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.

J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

PMID:
21649727
8.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

9.

High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.

Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F, Bergin C.

Int J STD AIDS. 2011 Oct;22(10):571-6. doi: 10.1258/ijsa.2011.010416.

PMID:
21998177
10.

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.

Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

11.

Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.

Chew KW, Allen SA, Taylor LE, Rich JD, Feller E.

J Clin Gastroenterol. 2009 Aug;43(7):686-91. doi: 10.1097/MCG.0b013e31818dd94c. Erratum in: J Clin Gastroenterol. 2009 Nov-Dec;43(10):1010.

12.

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Moon C, Jung KS, Kim do Y, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH.

Dig Dis Sci. 2015 Feb;60(2):573-81. doi: 10.1007/s10620-014-3361-6. Epub 2014 Sep 19.

PMID:
25236421
13.

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.

Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.

Ann Hepatol. 2013 Mar-Apr;12(2):228-35.

PMID:
23396734
14.

Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.

Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN.

Dig Dis Sci. 2009 Dec;54(12):2699-705. doi: 10.1007/s10620-008-0683-2.

PMID:
19148751
15.

Hepatitis C treatment outcomes in Australian clinics.

Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz JJ, Haber PA, George J, Dore GJ.

Med J Aust. 2012 Jun 4;196(10):633-7.

PMID:
22676878
16.

Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.

Dogan UB, Akin MS, Yalaki S.

World J Gastroenterol. 2013 Dec 14;19(46):8678-86. doi: 10.3748/wjg.v19.i46.8678.

17.
18.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
19.

Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.

El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.

World J Gastroenterol. 2014 Apr 28;20(16):4681-91. doi: 10.3748/wjg.v20.i16.4681.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk